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1 
SECRETED TUMOR-ASSOCIATED 
CYTOCHROME AS A BLOOD-BASED 
BIOMARKER FOR CANCER 
RELATED APPLICATIONS 
This application claims priority under 35 U.S.C. 119(e) to 
provisional application No. 61/701,449 filed Sep. 14, 2012, 
the disclosure of which is incorporated herein in its entirety. 
BACKGROUND OF THE INVENTION 
The present invention relates generally methods for the 
detection and diagnosis of cancer in a subject. More par-
ticularly, the invention relates to methods and kits for 
detecting Pgrmcl (progesterone receptor membrane compo-
nent 1) in a bodily fluid sample to facilitate the detection and 
diagnosis of cancer, particularly lung cancer. 
Cancer is one of the leading causes of death, and there is 
an urgent need for new biomarkers and therapeutic targets 
and method for early detection of cancer. Lung cancer is the 
leading cause of cancer death worldwide, resulting in 150, 
000 deaths per year in the United States. The mortality rate 
from lung cancer is greater than the combined mortality 
from breast, prostate and colorectal cancers. On the basis of 
morphology, lung cancer can be broadly classified into four 
main categories namely, adenocarcinoma, squamous cell 
carcinoma, large cell undifferentiated carcinoma and small 
cell carcinoma. Both squamous cell carcinoma and small 
cell carcinoma are strongly associated with a smoking 
history. 
Adenocarcinoma, squamous cell carcinoma, and large cell 
undifferentiated carcinoma are usually referred as "non-
small cell carcinoma." They are relatively chemo-resistant, 
and hence the mainstay of treatment is surgery. By contrast, 
small cell carcinoma has a higher propensity for distant 
metastases and is mainly treated by chemotherapy. 
While biopsy can be used to diagnose various cancers, it 
2 
2007, 105:16-36). Recently, Pgrmcl was identified as a 
sigma-2 receptor (S2R), with a clear role in tumor cell 
survival. 
Pgrmcl is also induced in multiple tumor types. For 
5 example, Pgrmcl is induced in approximately approxi-
mately one-half of breast tumors compared to matched 
nonmalignant tissue, and Pgrmcl is enriched in estrogen 
receptor-negative breast tumors (Crudden et al., Tumour 
Biol 2005, 26:142-6; Neubauer et al., Breast Cancer Res 
10 2008, 10:R85). In ovarian cancer, Pgrmcl expression 
increases with tumor stage, and Pgrmcl is also enriched in 
colon and lung cancers (Peluso et al., J Clin Endocrinol 
Metab 2008, 93:1592-9; Letwin et al., Cancer Res 2005 
65:1814-21; Irby et al., Cancer Res 2005, 65:1814-21; 
15 Difilippantonio et al., Eur J Cancer 2003; 39:1936-47). The 
mechanism through which Pgrmcl is induced in tumors is 
unclear, but may include induction by carcinogenic com-
pounds (Difilippantonio 2003; Selmin et al., Carcinogenesis 
1996; 17:2609-15; Nie et al., Mo! Carcinog 2006; 45:914-
20 33). Pgrmcl is inhibited by a small molecule ligand called 
AG-205, which inhibits growth in tumor cells and decreases 
EGFR levels (Ahmed et al., J Pharmacol Exp Ther 2010, 
333:564-73; Ahmed et al., J Biol Chem 2010, 285:24775-
82). Pgrmcl also contributes to multiple features of tumor 
25 growth. In lung adenocarcinoma cells, Pgrmcl promotes 
proliferation, anchorage-independent growth, migration, 
primary tumor growth and metastasis (Ahmed et al., J 
Pharmacol Exp Ther 2010). Pgrmcl has a similar biological 
role in ovarian cancer, where it regulates tumor growth as 
30 well as angiogenesis and tumor pathology (Peluso et al., 
Endocrinology 2009, 150:4846-54). Pgrmcl also suppresses 
apoptosis in immortalized granulosa and ovarian cancer 
cells (Peluso et al., Endocrinology 2006, 147:3133-40; 
Peluso et al., J Clin Endocrinol Metab 2008, 93: 1592-9) and 
35 contributes to mitotic progression in ovarian cancer (Lodde 
et al., Biol Reprod 2010, 84:215-222). Pgrmcl is inhibited 
by a small molecule ligand called AG-205, which inhibits 
growth in tumor cells and decreases EGFR levels (Yoshitani 
et al., Proteomics 2005, 5:1472-80; Ahmed et al., J Phar-
40 macol Exp Ther 2010; Ahmed et al., J Biol Chem 2010. is an invasive procedure and, therefore, less than desirable. 
Other diagnostic methods for cancers include ultrasound and 
computed tomography (CT) scan. Nonetheless, methods and 
kits for detecting biomarkers associated with cancer, par-
ticularly biomarkers present in a blood or serum sample, are 
urgently needed to facilitate early detection and treatment of 45 
SUMMARY OF THE INVENTION 
The invention described herein relates to methods that 
facilitate the diagnosis of cancer in a subject, determining 
the stage of the cancer, and determining the prognosis for 
and/or treatment of a subject having a cancer, e.g., a lung 
cancer. Prior to this invention Pgrmcl was not known to be 
a secreted protein and was not detected in bodily fluids, e.g. 
cancer. 
EGFR (epidermal growth factor receptor) is one of the 
most promising therapeutic targets in lung cancer, and 
EGFR inhibitors have produced positive clinical results, 
particularly for patients with activating mutations in the 
EGFR kinase domain (Gazdar A F., Oncogene 2009,28 
Suppl 1:S24-31; Lynch et al., The New England Journal of 
Medicine 2004; 350:2129-39; Pao et al., Proc Natl Acad Sci 
USA 2004; 101: 13306-11 ). 
50 blood, plasma or serum, or in subfractions of such fluids, 
e.g., exosome-containing fractions. Thus, secreted Pgrmcl 
is a biomarker for detecting the presence of cancer in a 
subject and for monitoring cancer progression in a subject 
by assaying its levels in a bodily fluid. 
An aspect of this invention is a method for detecting 
cancer in a subject by measuring the levels of Pgrmcl in a 
bodily fluid, wherein the level of Pgrmcl in a bodily fluid 
facilitates determining whether a subject has a cancer. Mea-
suring the levels of Pgrmcl in a bodily fluid is also useful in 
Pgrmcl (progesterone receptor membrane component) is 55 
a microsomal protein that colocalizes with EGFR in the 
endoplasmic reticulum or punctate cytoplasmic sites. 
Pgrmcl associates with EGFR in lung cancer cells and 
increases susceptibility to the EGFR inhibitor erlotinib, it is 
also a cytochrome b5 related protein. (Hughes et al., Cell 
Metab 2007; 5:143-9; Ahmed et al., J Biol Chem 2010, 
285:24775-82; Crudden, Chitti and Craven R J., J Pharma-
col Exp Ther 2006, 316:448-55; Nolte et al., Biochim 
Biophys Acta 2000; 1543:123-30; Peluso, Romak, and Liu, 
Endocrinology 2008; 149:534-43; Min et al., FEBS J 2005, 
272:5832-43; Mifsud and Bateman, Genome Biol 2002, 3: 
60 assessing the stage of the cancer, particularly stage 1 lung 
cancer where the cancer limited to the lung and hasn't spread 
to the lymph nodes and wherein the tumor is generally 
smaller, e.g., less than about 2 inches (5 centimeters) across. 
Also described herein are methods for monitoring the pro-
65 gression of a cancer in a subject. 
Thus the methods of the invention can also be used to 
RESEARCH0068; Cahill, J Steroid Biochem Mo! Biol assess cancer status, particularly lung cancer status, in a 
US 10,288,626 B2 
3 
subject. "Cancer status" in the context of the present inven-
tion includes, inter alia, the presence or absence of disease, 
the risk of developing disease, the stage of the disease, and 
the effectiveness of treatment of disease. Based on this 
status, further procedures may be indicated, including addi- 5 
tional diagnostic tests or therapeutic procedures or regimens, 
such as endoscopy, biopsy, surgery, chemotherapy, immu-
notherapy, and radiation therapy. 
The invention also contemplates a kit for use in detecting 
and diagnosing cancer in a subject, thereby assessing cancer 10 
status in a subject. Kits within the invention comprise, for 
example, and antibody that specifically binds to Pgrmcl, 
e.g., a polyclonal or monoclonal antibody that binds to 
native Pgrmcl, or denatured Pgrmc 1, preferably an antibody 
that binds to a native Pgrmcl, and directions for detecting 15 
Pgrmcl in a bodily fluid sample. The kit may also include a 
control reference, indicating the levels of Pgrmcl in a 
subject without cancer (a negative control reference) or 
indicating the levels of Pgrmcl in a subject with a cancer (a 
positive control reference). The positive control references 20 
may indicate the levels of Pgrmcl in subjects having a 
cancer, e.g., a lung cancer, a breast cancer, an ovarian cancer, 
an oral cancer or a head or neck cancer. 
4 
panel, lane 1 ). (D) Adenoviruses driving the expression of a 
control protein (Lacz, solid line) or a heme-binding-defi-
cient mutant of Pgrmcl (Pgr-hbd, dashed line) demonstrated 
that the inactive Pgrmcl protein inhibited H226 cell growth. 
Cells were maintained in media lacking serum for the 
indicated times. (E) The expression of the exogenous 
Pgrmcl-hbd protein was detected by western blot in NCI-
H226 cells infected with a control adenovirus (lane 1 ), 
encoding Lacz, or the Pgrmcl-hbd expression virus (lane 2). 
The top panel was probed with an antibody to the HA 
epitope tag sequence, with which Pgrmcl-hbd is fused. (F) 
NCI-H226 cells were treated with increasing doses of the 
Pgrmcl inhibitor AG-205 and maintained with serum 
(dashed line) or without serum (solid line) for 96 hours. 
AG-205 caused a loss of viability in the absence of serum in 
the SCLC cell line. 
FIG. 3 depicts elevated Pgrmcl expression in tumors of 
matched adenocarcinoma clinical samples. (A) Pgrmcl 
expression was determined by western blot in non-malignant 
tissue (gray bars) and paired tumors (black bars) from the 
same patient. The Y-axis refers to the fold change relative to 
a non-malignant tissue sample that was included in each 
western blot. Analyses were performed in triplicate, and 
Pgrmcl was significantly elevated in 6/15 samples. (B) A 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts elevated Pgrmcl expression in tumors of 
matched squamous cell lung carcinoma (SCLC) clinical 
samples. (A) Pgrmcl expression was determined by western 
blot in non-malignant tissue (gray bars) and paired tumors 
(black bars) from the same patient. The Y-axis refers to the 
fold change relative to a non-malignant tissue sample that 
was included in each western blot. Analyses were performed 
25 Pgrmcl-specific antibody recognized elevated Pgrmcl 
expression in an adenocarcinoma (upper panel, lane 2) 
compared to matched normal tissue (upper panel, lane 1), 
and the reactive band was blocked by the addition of the 
immunogenic peptide. A Coomassie Brilliant Blue (CBB) 
30 stained gel of the samples showed approximately equal 
protein loading (lower panel). (C) Pgrmcl levels correlate 
with survival. Adenocarcinoma patients were stratified by 
high and low tumor Pgrmcl levels. Patients with lower 
Pgrmcl expression had an increased overall survival in triplicate, and Pgrmcl was significantly elevated in 12/15 
samples. Throughout, *=s0.05, **=s0.01 and ***s=0.005. 
(B) A Pgrmc I-specific antibody recognized elevated Pgrmc 1 
expression in an SCLC tumor (upper panel, lane 2) com-
pared to matched normal tissue (upper panel, lane 1). The 
migration of molecular weight markers is indicated on the 
left of the figure. The 25 kDa reactive band was blocked by 40 
the addition of immunogenic peptide (second panel), and 
pre-immune serum (PIS) from the antibody-producing host 
failed to react with the bands (third panel). A Coomassie 
Brilliant Blue (CBB) stained gel of the samples showed 
approximately equal protein loading (lower panel). (C) An 45 
increased fraction of poorly differentiated tumors had 
elevated Pgrmcl levels. Differentiation status was deter-
mined by a certified pathologist, and Pgrmcl levels were 
plotted by differentiation status. The averages for each group 
are indicated by a horizontal line. (D-G) Immunohistochem- 50 
istry for Pgrmcl (brown staining) in the normal tissue (D) 
and tumor (E) in patient #4 from panel A identified strong 
focal staining for Pgrmcl in the tumor as well as stainin in 
the adjecent non-epithelial cells. An image of panel F at 
higher magnifications shown in the inset. 
35 (p=0.035). (D) Immunohistochemistry of Pgrmcl (D and F) 
and cytokeratins (E and F) in normal (D and E) and tumor 
(F and G) tissue. Pgrmcl levels were moderate in normal 
tissue, which contained abundant epithelial cells and was 
elevated in tumors, with diffuse staining compared to cytok-
eratins. 
FIG. 4 depicts Pgrmcl is elevated in plasma from lung 
cancer patients. (A) Plasma samples were partially purified 
by binding to Cibacron Blue colunms. Pgrmcl was analyzed 
by western blot of the colunm supernatants (upper panel), 
while the lower panel shows Coomassie brilliant blue stain-
ing of the samples. An equal volume was analyzed in each 
gel, and the sample in lane 5 was included in each gel or 
western blot as an internal reference. The tumor types 
included squamous (q), small cell (s) and adenocarcinoma 
(a). (B) Samples were analyzed in triplicate and plotted 
relative to the intensity of sample C2 (panel B; lane 5, panel 
A). "N" indicates normal controls, non-cancer patients, 
while "C" refers to cancer patients. (C) Plasma Pgrmcl 
levels from 4 non-cancer patients were compared with those 
FIG. 2 depicts Pgrmcl expression and biological activity 
55 of patients with adenocarcinoma (adeno, N=4), squamous 
cell lung cancer (N=3) and large cell lung cancer (N=2), 
respectively, where each was measured in triplicate. Pgrmcl 
levels were determined relative to sample C2 as described in 
in SCLC cell lines. (A) Pgrmcl expression was tested in a 
group of 3 commonly used SCLC cell lines (upper panel), 
and ku70 was used as a loading control (lower panel). (B) 
Pgrmcl expression was inhibited by siRNA transfection in 60 
H226 cells, resulting in a significant loss of viability for 
Pgrmcl-inhibited cells (siPGR, dashed line) relative to 
control cells (si CON, solid line). Cells were maintained in 
medium lacking serum for the indicated time and in all 
cases, viability was determined by cell counting. (C) Pgrmcl 65 
expression was inhibited by siRNA transfection (upper 
panel, lane 2) relative to the control transfection (upper 
panel B, above, and the average and standard deviation was 
calculated for each group. (D) An antibody to Pgrmcl 
reacted positively in a plasma sample (top panel). Pre-
immune serum from the same host animal did not react with 
the Pgrmcl band (center panel), and the reactive band was 
blocked by the addition of immunogenic peptide (lower 
panel). 
FIG. 5 demonstrates that Pgrmcl is secreted by lung 
cancer cell lines and promotes proliferation. (A) Condi-
US 10,288,626 B2 
5 
tioned media from A549 cells expressing a control shRNA, 
lane 1, or an shRNA targeting Pgrmcl (lane 2), were 
analyzed by western blot. Top panel: Pgrmcl was readily 
detectable in conditioned media (lane 1) and decreased in 
cells in which Pgrmcl expression was inhibited (lane 2). 
Lower panels: the intracellular proteins GST-Pl and ku70 
were undetectable in conditioned media but abundant in 
cellular lysates. (B) FACS analysis of A549 control cells 
showed no evidence of cell death (large peak is G 1 ; right is 
G2/M). (C) Pgrmcl was detected by western blot in condi-
tioned media from NCI-H226 cells. For both A and B, the 
conditioned medium was collected after 24 hours in serum-
free medium and concentrated 10-fold prior to analysis. 
(D-E) Purified, recombinant Pgrmcl was added in increas-
ing doses to A549 NSC LC cells (D) or NCI-H226 SCLC 
cells (E) for 72 hours, and proliferation was measured by 
mean cell count (solid line) or MTT assay (dashed line). 
Proliferation relative to cells treated with the vehicle control 
is plotted on they-axis. (F) H226 SCLC cells were trans-
fected with a plasmid encoding GFP-Pgrmcl, and cells were 
visualized by fluorescence microscopy (top) or bright field 
(bottom). 
FIG. 6 depicts Pgrmcl expression in plasma and tumors 
by stage. (A) Western blot of plasma Pgrmcl levels in stage 
1-4 lung tumors. Samples were prepared and analyzed using 
the protocol described in FIG. 4. The lower panel shows a 
loading control-the same samples separated by SDS-PAGE 
and stained with Coomassie Brilliant Blue. (B) Quantitation 
of the results from part A. Stage 1 tumors had significantly 
higher plasma Pgrmcl levels than those of patients with 
stage 2, 3 and 4 tumors. (C) Immunohistochemistry of stage 
1 (n=l0), stage 2 (n=l0) and stage 3 (n=12) lung adenocar-
cinomas showing no significant increase with tumor stage. 
(D) Immunohistochemistry of stage 1 (n=12), stage 2 (n=13) 
and stage 3 (n=29) squamous cell lung carcinomas, showing 
a significant decrease in Pgrmcl staining from stage 1 to 
stage 2 tumors that remained in stage 3 tumors. Stage 2 and 
3 tumors were not significantly different. We conclude that 
Pgrmcl levels in plasma are significantly higher in early 
stage lung tumors. This difference may reflect differences in 
Pgrmcl secretion during the development of lung cancer. 
DETAILED DESCRIPTION 
Pgrmcl is induced by carcinogens in animal models, but 
previous studies in clinical tumor samples have been limited 
6 
Pgrmcl dominant-negative mutant or (iii) the Pgrmcl 
inhibitor AG-205. In adenocarcinomas, 6/15 tumors signifi-
cantly over-expressed Pgrmcl, and tumor Pgrmcl levels 
correlated with patient survival. Pgrmc 1 localizes to secre-
5 tory vesicles in cancer cells, and Pgrmcl was secreted by 
lung cancer cells. In addition, elevated Pgrmcl was detected 
in women with early stage lung adenocarcinoma and in large 
cell lung cancer compared to men (p=0.02 and 0.05, respec-
tively). Pgrmcl was also elevated in tumor-adjacent 
10 inflamed tissue (p=0.03, t-test). 158 head and neck tumors 
were analyzed and Pgrmcl levels were found in modest but 
detectable amounts in normal head and neck tissue but were 
elevated in head and neck cancer. The Pgrmcl levels were 
elevated in grade 1 versus grade 2 head and neck tumors 
15 (p=0.007, t-test) , and were also elevated by stage (p=0.002, 
t-test). Elevated Pgrmcl levels were also detected in neu-
roblastoma compared to normal peripheral nerve, and 
Pgrmcl was also abundant in neuroblastoma cell lines. 
Kaplan-Meier plot of lung cancer patient survival (FIG. 3C) 
20 among high and low Pgrmcl-expressing tumors. Patients 
with tumors having lower Pgrmcl levels had an increased 
overall survival (p=0.01) than those having tumors express-
ing higher levels of Pgrmcl. Similar results were seen in 
ovarian cancer but not in breast cancer, where Pgrmcl was 
25 universally regulated and showed no correlation with sur-
vival or hormone receptors. 
Plasma samples from subjects with lung cancer and 
normal controls ( subjects without cancer) were analyzed and 
it was found that Pgrmcl was significantly elevated in the 
30 plasma of lung cancer patients compared to non-cancer 
patients (FIG. 4). Together, the results demonstrate that 
Pgrmcl is a serum biomarker for cancer, as well as a 
therapeutic target, for cancer, particularly lung cancer. 
Diagnostic strategies for cancer include expensive imag-
35 ing procedures that can only be performed at a few sites in 
the area, whereas a blood test could be performed at a distant 
site and a reduced cost. The levels of Pgrmcl in bodily 
fluids, particularly in blood, plasma, and serum, is an 
effective indicator of cancer, and in accordance with the 
40 methods described here can be used to detect cancer, either 
alone or in combination with other biomarkers, and the 
levels of Pgrmcl may be used to predict therapeutic out-
come, either to Pgrmcl inhibitors or other classes of drugs. 
In the methods described herein the detection of Pgrmcl, 
45 or combinations of Pgrmc 1 and other cancer biomarkers, in 
a bodily fluid sample, e.g., the blood, plasma or serum, of a 
subject is used to evaluate a subject for risk of having a 
cancer, e.g., a lung cancer or a head or neck cancer. The 
methods described herein also facilitate the identification of 
by the availability of key clinical endpoints. We have 
determined the expression of Pgrmcl in matched lung 
cancer samples, and found that Pgrmcl was elevated in 80% 
squamous cell lung cancers and 40% lung adenocarcinomas. 50 
In the latter disease, elevated Pgrmcl expression correlated 
with overall survival, while Pgrmcl correlated with differ-
entiation state in the former. We have also determined the 
the stage of cancer in a subject. In the methods of this 
invention the cancer may be e.g., lung cancer, breast cancer, 
ovarian cancer, oral cancer, or head or neck cancer, in 
particular lung cancer, e.g., SCLC and lung adenocarcino-
mas, and head or neck cancer, and preferably a stage 1 lung Pgrmcl is secreted by cancer cells, albeit at lower than 
intracellular levels and that purified, recombinant Pgrmcl 55 
stimulates the growth of cancer cells. Pgrmcl is also sig-
nificantly elevated in the bloodstream of the majority of 
cancer patients, while it was present at low levels in non-
cancer control donors. 
cancer. 
In the methods described herein the bodily fluid samples 
include blood, serum, plasma, saliva, tears or urine, or an 
exosome-containing fraction of such samples. Preferably the 
bodily fluid sample is blood, plasma, or serum, or an 
As discussed herein, Pgrmcl expression in clinical tumor 
samples from squamous cell lung cancers (SCLC) and lung 
adenocarcinomas was analyzed compared to corresponding 
non-malignant tissue. Pgrmcl expression increased signifi-
cantly (ps0.05) in 12/15 SCLC samples and was elevated in 
poorly differentiated tumors. Pgrmcl was highly expressed 
in SCLC cell lines, and SCLC cell survival was inhibited by 
(i) siRNA knockdown of Pgrmcl, (ii) expression of a 
60 exosome-containing fraction thereof. 
A "subject" in the context of the present invention is an 
animal, preferably a mammal. The mammal can be a human, 
non-human primate, mouse, rat, dog, cat, horse, or cow, but 
are not limited to these examples. In various exemplary 
65 embodiments, a subject is human and may be referred to as 
a patient. Mammals other than humans can be advanta-
geously used as subjects that represent animal models of a 
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disease or for veterinarian applications. A subject can be one 
who has been previously diagnosed or identified as having 
a cancer, and optionally has already undergone, or is under-
going, a therapeutic intervention for a cancer. Alternatively, 
a subject can also be one who has not been previously 5 
diagnosed as having a cancer. For example, a subject can be 
one who exhibits one or more risk factors for a cancer, or one 
who does not exhibit a cancer risk factor, or one who is 
asymptomatic for a cancer. A subject can also be one who is 
suffering from or at risk of developing a cancer. In certain 10 
embodiments, the subject can be already undergoing therapy 
or can be a candidate for therapy. 
An aspect of this invention is a method for facilitating in 
the detection or diagnosis of the cancer in a subject ( e.g., a 
human patient) comprises (a) obtaining a bodily fluid sample 15 
from a test subject, (b) determining the level of Pgrmcl in 
the test subject and (c) comparing the Pgrmcl level in the 
sample of the test subject to the Pgrmcl level of a positive 
or negative control, wherein an elevated level of Pgrmcl in 
the sample of the test subject as compared to a negative 20 
reference level is indicative of a higher risk of the test 
subject having a cancer. A negative reference level, or 
negative control, could be, e.g., the level of Pgrmcl in a 
bodily fluid sample from a subject who does not have cancer, 
while a positive reference level, or positive control, could 25 
be, e.g., the level of Pgrmcl in a bodily fluid sample from 
a subject known to have a cancer, e.g., a lung cancer. The 
bodily fluid sample could be, e.g., a blood, plasma or serum 
sample. 
In accordance with the present invention, Pgrmcl levels 30 
are "elevated" or "increased" if the levels in fluid samples of 
a test subject are higher than the Pgrmcl levels in a 
comparable sample from a subject, or subjects, without 
cancer. For example, if the level of Pgrmcl in the test 
sample, e.g., a blood, plasma or serum sample, is at least 35 
2-fold, 4-fold, 6-fold, 10-fold, 15-fold, 20-fold greater, 
25-fold or 30-fold greater than the level of Pgrmcl in a 
comparable sample, e.g., a blood, plasma or serum sample, 
from a subject without a cancer then the levels of Pgrmcl are 
considered to be "elevated" or "increased" and indicative of 40 
an increased risk of the test subject having a cancer, par-
ticularly a lung cancer, or a head or neck cancer. Detecting 
such elevated levels of Pgrmcl facilitates the diagnosis of a 
subject as having a cancer and also facilitates the determi-
nation of the progression or regression of a cancer, wherein 45 
elevated levels of Pgrmcl in samples obtained from a test 
subject at various times over the levels of Pgrmcl in a 
subject without cancer is indicative of the progression of the 
cancer. In particular, a level of Pgrmcl in a bodily fluid 
sample from a test subject that is at least eight-fold or at least 50 
ten fold greater than the levels found in a comparable 
negative control, e.g., bodily fluid sample from a subject 
without cancer, is indicative of an elevated risk of the test 
subject having a cancer, particularly a lung cancer, or a head 
or neck cancer. In another aspect of this invention, Pgrmcl 55 
levels are elevated if the levels in the samples from the test 
subject are significantly (p<0.01) higher than the levels of 
Pgrmcl in a comparable sample from a subject, or subjects, 
without cancer. 
8 
invention, if the level of Pgrmcl in the test sample is about 
ten-fold or at least ten fold greater than the levels found in 
a comparable negative control sample, such elevated levels 
are indicative of an elevated risk of the test subject having 
an early stage cancer, particularly an early stage lung cancer, 
e.g., stage 1 lung cancer. 
An aspect of this invention is a method for facilitating the 
screening or diagnosis of a subject for cancer. The method 
comprises the steps of: obtaining a body fluid from the 
subject; and measuring the secreted Pgrmcl levels in the 
bodily fluid to facilitate the screening or diagnosis of the 
subject for cancer. For example, the method comprises the 
steps of: a) isolating or obtaining a bodily fluid sample, e.g., 
blood, plasma or serum, from a subject to be tested (i.e., "test 
sample"); b) determining the levels of Pgrmcl in the test 
sample, c) comparing the levels of Pgrmcl in the test sample 
to the levels of Pgrmcl in a reference sample, wherein an 
increase or decrease in Pgrmcl levels over the level in the 
reference sample is indicative of the cancer. The subject to 
be tested may be, e.g., an individual suspected of having, or 
who has a cancer, e.g., a lung cancer. In certain embodi-
ments, the Pgrmcl level in the reference sample may be the 
level in samples collected from the test subject or from a 
different subject. For example, a baseline Pgrmcl level can 
be determined from an analysis of samples from the same 
subject at different time points. Alternatively, the Pgrmcl 
level in a reference sample could be the level obtained based 
on the analysis of samples taken from control subjects 
sharing one or more of gender, age, or weight with the test 
subject. The bodily fluid samples may be, e.g., blood, serum, 
plasma, saliva, tears or urine or an exosome-containing 
fraction thereof. Preferably the biological fluid sample is 
blood, plasma, or serum, or an exosome-containing fraction 
thereof. The reference sample may be a negative reference 
sample, or negative control sample, wherein the sample is 
from a subject who does not have cancer. Alternatively the 
reference sample may be a positive reference sample, or a 
positive control sample, wherein the sample is from a 
subject who has a cancer, preferably the type of cancer that 
test subject is suspected of having. 
In the methods described herein the cancer is detected 
when the secreted Pgrmc 1 level in the body fluid is increased 
relative to the secreted Pgrmcl level in the sample from the 
reference, or control, sample. A negative reference sample 
may be, e.g., a body fluid of an individual without cancer or 
the negative reference sample may be, e.g., the average 
levels of Pgrmcl derived from population studies on sub-
jects who did not develop cancer. 
In methods wherein the reference sample is a negative 
reference sample, the cancer is detected when the secreted 
Pgrmcl level in the body fluid is increased relative to the 
secreted Pgrmcl level in the body fluid of a subject without 
cancer. In methods wherein the reference sample is a posi-
tive reference sample, the cancer is detected when the 
secreted Pgrmcl levels are higher than of not significantly 
different then the levels in the positive reference sample. 
Also an aspect of this invention is a method of detecting 
the presence of a cancer in an individual, wherein the 
individual is suspected of having, or has a cancer, said 
method comprising: a) contacting a test bodily fluid sample 
from the individual with an antibody that specifically binds 
to Pgrmcl; b) detecting the level of Pgrmcl in the test 
sample that specifically binds the antibody; and, c) compar-
ing the level of Pgrmcl in the test sample to the level of 
The methods of this invention are useful in detecting an 60 
early stage cancer wherein the cancer cells are localized and 
metastasis to lymph nodes or to another organ has not been 
detected, e.g. stage 1 lung cancer, or a late stage cancer 
where in the cancer has metastasized and is found in the 
lymph nodes or in more than one organ. The methods of this 
invention are particularly useful in detecting early stage 
cancers, e.g. stage 1 lung cancer. In an aspect of this 
65 Pgrmcl that specifically binds the antibody in a correspond-
ing normal bodily fluid sample; wherein an elevated level of 
Pgrmc 1 in the test sample relative to the normal sample is an 
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indication of the presence of the cancer in the individual. A 
normal bodily fluid sample is a bodily fluid sample from an 
individual who does not have cancer. If the antibody binds 
10 
by the modification of whole antibodies or those synthesized 
de nova using recombinant DNA technologies. The term 
"antibody" refers to both monoclonal and polyclonal anti-
bodies. Antibodies can be antagonists, agonists, neutraliz-to other proteins in the samples in addition to Pgrmcl, 
alternatively, the level of protein binding to the antibody in 
the samples may be compared and an elevated level of 
protein binding the antibody in the test sample relative to the 
level of protein binding the antibody the normal sample is an 
indication of the presence of the cancer in the individual. 
5 ing, inhibitory or stimulatory. 
The bodily fluid sample to be assayed for levels of 
Pgrmc 1 in the methods of this invention may be from any 
subject, e.g., a subject having a cancer or suspected of 
having a cancer, a subject who smokes, a subject who has a 
The invention described herein also includes methods for 
monitoring the progression or regression of cancer in a 
patient who has a cancer, by: a) contacting a first bodily fluid 
sample from the patient with an antibody that specifically 
binds Pgrmcl and quantitatively determining the level of 
protein in the sample that specifically binds the antibody; b) 
contacting a second bodily fluid sample from the patient 
with an antibody that specifically binds Pgrmcl and quan-
titatively determining the level of Pgrmcl in the sample that 
specifically binds the antibody, wherein the second sample 
10 family history of cancer, e.g., lung cancer or a head or neck 
cancer, a subject who is exposed to carcinogenic agents, or 
a subject having a chronic cough. 
The level of Pgrmcl in a bodily fluid may be detected by 
a variety of methods, e.g., immunoassays. Immunoassays 
15 carried out in accordance with the present invention may be 
homogeneous assays or heterogeneous assays and may be 
used for the qualitative and/or the quantitative assessment of 
Pgrmcl in a bodily sample. In a homogeneous assay the 
immunological reaction usually involves the specific anti-
20 body (e.g., anti-Pgrmcl protein antibody), a labeled analyte, 
and the sample of interest. The signal arising from the label 
is modified, directly or indirectly, upon the binding of the 
antibody to the labeled analyte. Both the immunological 
reaction and detection of the extent thereof can be carried 
is obtained at a period of time after the first sample is 
obtained; and c) comparing the level of Pgrmcl bound to the 
antibody in the first sample to the level of Pgrmcl bound to 
the antibody in the second sample, wherein a difference in 
the levels is indicative of the progression or regression of the 
cancer, wherein increasing levels of Pgrmcl is indicative of 25 
a progressing cancer. If the antibody binds to other proteins 
in the samples in addition to Pgrmcl, the level of protein 
binding to the antibody in the samples may be compared and 
an elevated level of protein binding the antibody in the test 
sample relative to the level of protein binding the antibody 30 
the normal sample is an indication of the presence of the 
cancer in the individual. The test subject may be, e.g., a 
subject who has received one or more therapeutic treatments 
for a cancer. 
Another aspect of this invention is a method for assessing 35 
the risk of a subject for having cancer, comprising: detecting 
the level of a Pgrmcl in a sample from test subject and 
comparing the detected level with a reference level, wherein 
a level in the sample of the test subject below the reference 
level is indicative of a lower risk of the test subject having 40 
cancer; and wherein a level in the sample of the test subject 
above the reference level is indicative of a higher risk of the 
test subject having cancer. 
out in a homogeneous solution. Immunochemical labels 
which may be employed include free radicals, radioisotopes, 
fluorescent dyes, enzymes, bacteriophages, or coenzymes. 
In a heterogeneous assay approach, the reagents are 
usually the sample, the antibody, and means for producing a 
detectable signal. Samples as described above may be used. 
The antibody can be immobilized on a support, such as a 
bead ( such as protein A and protein G agarose beads), plate 
or slide, and contacted with the specimen suspected of 
containing the antigen in a liquid phase. The support is then 
separated from the liquid phase and either the support phase 
or the liquid phase is examined for a detectable signal 
employing means for producing such signal. The signal is 
related to the presence of the analyte in the sample. Means 
for producing a detectable signal include the use of radio-
active labels, fluorescent labels, or enzyme labels. For 
example, if the antigen to be detected contains a second 
binding site, an antibody which binds to that site can be 
conjugated to a detectable group and added to the liquid 
phase reaction solution before the separation step. The The antibodies useful in the methods of this invention 
include polyclonal antibodies and monoclonal antibodies 
that bind Pgrmcl. The antibodies may bind specifically to a 
denatured form of Pgrmcl or may bind to the nondenatured 
form of Pgrmcl or both. Preferably, the antibody binds to the 
nondenatured form of Pgrmcl. Antibodies that bind to 
Pgrmcl are well-known in the art and are commercially 
available. 
45 presence of the detectable group on the solid support indi-
cates the presence of the antigen in the test sample. 
Examples of suitable immunoassays include, but are not 
limited to oligonucleotides, immunoblotting, immunopre-
cipitation, immunofluorescence methods, chemilumines-
50 cence methods, electrochemiluminescence (ECL) or 
enzyme-linked immunoassays. 
As used herein, the term "antibody" means a protein 
comprising one or more polypeptides substantially encoded 
by all or part of the recognized immunoglobulin genes. The 
recognized immunoglobulin genes, for example in humans, 55 
include the kappa (K), lambda (A) and heavy chain genetic 
loci, which together compose the myriad variable region 
genes, and the constant region genes mu (µ), delta (o), 
gamma (y), epsilon (E) and alpha (a), which encode the IgM, 
IgD, IgG, IgE, and IgA isotypes respectively. Antibody 60 
herein is meant to include full length antibodies and anti-
body fragments, and may refer to a natural antibody from 
any organism, an engineered antibody or an antibody gen-
erated recombinantly for experimental, therapeutic or other 
purposes as further defined below. Antibody fragments 65 
include Fab, Fab', F(ab')2 , Fv, scFv or other antigen-binding 
subsequences of antibodies and can include those produced 
Those skilled in the art will be familiar with numerous 
specific immunoassay formats and variations thereof which 
may be useful for carrying out the method disclosed herein. 
See generally E. Maggio, Enzyme-Immunoassay, (1980) 
(CRC Press, Inc., Boca Raton, Fla.); see also U.S. Pat. No. 
4,727,022 to Skold et al., titled "Methods for Modulating 
Ligand-Receptor Interactions and their Application," U.S. 
Pat. No. 4,659,678 to Forrest et al., titled "Immunoassay of 
Antigens," U.S. Pat. No. 4,376,110 to David et al., titled 
"Immunometric Assays Using Monoclonal Antibodies," 
U.S. Pat. No. 4,275,149 to Litman et al., titled "Macromo-
lecular Environment Control in Specific Receptor Assays," 
U.S. Pat. No. 4,233,402 to Maggio et al., titled "Reagents 
and Method Employing Channeling," and U.S. Pat. No. 
4,230,797 to Boguslaski et al., titled "Heterogeneous Spe-
cific Binding Assay Employing a Coenzyme as Label." 
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Antibodies can be conjugated to a solid support suitable 
for a diagnostic assay (e.g., beads such as protein A or 
protein G agarose, microspheres, plates, slides or wells 
formed from materials such as latex or polystyrene) in 
accordance with known techniques, such as passive binding. 5 
Antibodies as described herein may likewise be conjugated 
The detection of the secreted Pgrmcl can he enhanced by 
using certain selectivity conditions, e.g., adsorbents or wash-
ing solutions, or by functionalizing the absorbent with e.g. 
an antibody that specifically binds Pgrmcl. However, other 
adsorbents can be used, as long as they have the binding 
characteristics suitable for binding Pgrmcl. 
to detectable labels or groups such as radiolabels (e.g., S35 , 
I125 , I131 )luminescent and enzyme labels (e.g., horseradish 
peroxidase, alkaline phosphatase, luciferase ), and fluores-
cent labels (e.g., fluorescein, green fluorescent protein, rho- 10 
damine) in accordance with known techniques. 
More particularly, armed with the information regarding 
Pgrmcl, various methods can be used to recognize patterns 
of doublets, triplets, and higher combinations ofbiomarkers 
according to the invention. These methods take raw data 
regarding which peaks are present and their intensity and 
Antibodies can also be useful for detecting post-transla-
tional modifications of Pgrmcl proteins, polypeptides, 
mutations, and polymorphisms, such as tyrosine phospho-
rylation, threonine phosphorylation, serine phosphorylation, 15 
glycosylation (e.g., O-GlcNAc). Such antibodies specifi-
cally detect the phosphorylated amino acids in a protein or 
proteins of interest, and can be used in immunoblotting, 
immunofluorescence, and ELISA assays. These antibodies 
are well-known to those skilled in the art, and commercially 20 
available. Post-translational modifications can also be deter-
provide a differential diagnosis of lung cancer versus normal 
for a sample. 
Thus, the process can be divided into the learning phase 
and the classification phase. In the learning phase, a learning 
algorithm is applied to a data set that includes members of 
the different classes that are meant to be classified, for 
example, data from a plurality of samples diagnosed as 
cancer and data from a plurality of samples assigned a 
negative diagnosis. The methods used to analyze the data 
include, but are not limited to, artificial neural network, 
mined using metastable ions in reflector matrix-assisted 
laser desorption ionization-time of flight mass spectrometry 
(MALDI-TOF) (Wirth et al., (2002) Proteomics 2(10): 
1445-51). 
In another aspect of the invention, the detection of 
Pgrmcl to facilitate in the diagnosis of cancer status entails 
contacting a sample from a subject with a substrate, e.g., a 
SELDI probe, having an adsorbent thereon, under conditions 
that allow binding between the Pgrmcl and the adsorbent, 
and then detecting the Pgrmc 1 bound to the adsorbent by gas 
phase ion spectrometry, for example, mass spectrometry. 
Other detection paradigms that can be employed to this end 
include optical methods, electrochemical methods (voltam-
etry and amperometry techniques), atomic force micros-
copy, and radio frequency methods, e.g., multipolar reso-
nance spectroscopy. Illustrative of optical methods, in 
addition to microscopy, both confocal and non-confocal, are 
detection of fluorescence, luminescence, chemilumines-
cence, absorbance, reflectance, transmittance, and birefrin-
gence or refractive index ( e.g., surface plasmon resonance, 
ellipsometry, a resonant mirror method, a grating coupler 
waveguide method or interferometry). 
Software used to analyze the data can include code that 
applies an algorithm to the analysis of the signal to deter-
mine whether the signal represents a peak in a signal that 
corresponds to a biomarker according to the present inven-
tion. The software also can subject the data regarding 
observed biomarker peaks to classification tree or ANN 
analysis, to determine whether a biomarker peak or combi-
nation of biomarker peaks is present that indicates lung 
cancer status. Analysis of the data may be "keyed" to a 
variety of parameters that are obtained either directly or 
indirectly from the mass spectrometric analysis of the 
sample. These parameters include, but are not limited to, the 
presence or absence of one or more peaks, the height of one 
or more peaks, the log of the height of one or more peaks, 
and other arithmetic manipulations of peak height data. 
In an embodiment of this invention, the detection of 
secreted Pgrmcl for diagnosis of cancer in a subject entails 
contacting a sample from a subject or patient, preferably a 
blood, plasma or serum sample, with a substrate having an 
adsorbent thereon under conditions that allow binding 
between the secreted Pgrmcl and the adsorbent, and then 
detecting the secreted Pgrmcl bound to the adsorbent by gas 
phase ion spectrometry, preferably by Surface Enhanced 
Laser Desorption/Ionization (SELDI) mass spectrometry. 
support vector machines, genetic algorithm and self-orga-
nizing maps and classification and regression tree analysis. 
These methods are described, for example, in WO O 1/31579, 
25 May 3, 2001 (Barnhill et al.); WO 02/06829, Jan. 24, 2002 
(Hitt et al.) and WO 02/42733, May 30, 2002 (Paulse et al.). 
The learning algorithm produces a classifying algorithm. 
The classifier is keyed to elements of the data, such as 
particular markers and particular intensities of markers, 
30 usually in combination, that can classify an unknown sample 
into one of the two classes. The classifier is ultimately used 
for diagnostic testing. 
Software, both freeware and proprietary software, is read-
ily available to analyze such patterns in data, and to devise 
35 additional patterns with any predetermined criteria for suc-
cess. Those biomarkers which by themselves are predictive 
of a differential diagnosis of lung cancer versus normal do 
not require pattern recognition software to analyze the data. 
In another aspect, the present invention provides kits for 
40 facilitating the diagnosis of cancer status, which kits are 
used to detect secreted Pgrmc 1 levels according to the 
invention. The kits screen for the presence of secreted 
Pgrmcl, or secreted Pgrmcl and combinations of other 
biomarkers that are differentially present in samples from 
45 normal subjects and subjects with cancer. 
The kits of this invention are useful for facilitating the 
detection of, or diagnosis or prognosis of a cancer by 
detecting Pgrmcl, or Pgrmcl and one or more biomarkers 
for a cancer, in a bodily fluid. The kit comprises biomarker 
50 detecting reagents for detecting the Pgrmcl and the one or 
more biomarkers, and instructions for using the reagents to 
detect the biomarkers from the bodily fluids and facilitating 
the diagnosis or prognosis of the cancer. As used herein, the 
term "biomarker detecting reagents" refers to any sub-
55 stances, antibodies, receptors, chemicals, solutions used in 
reactions and processes that are capable of detecting, mea-
suring, and examining Pgrmcl and any additional biomark-
ers and their isoforms of interest. In one embodiments, the 
cancer is lung cancer or head or neck cancer and the 
60 biomarker is Pgrmcl. In other preferred embodiments, the 
biomarker detecting reagents used herein comprise antibod-
ies that specifically bind to Pgrmcl, e.g. a polyclonal or 
monoclonal antibody that was raised against a Pgrmcl 
immunogenic fragment. For example, the kits may comprise 
65 a first monoclonal or polyclonal antibody raised against a 
peptide of Pgrmc 1, e.g., the peptide having the amino acid 
sequence QPAASGDSDDDE (SEQ ID NO:1). The kits of 
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this invention may comprise a second monoclonal or poly-
clonal, wherein the second antibody binds to the first anti-
body. The antibodies may be antibodies coupled to a detect-
able substance, which facilitates their detection. Examples 
of detectable substances include various enzymes, prosthetic 5 
groups, fluorescent materials, luminescent materials, biolu-
minescent materials, radioactive materials, positron emitting 
metals using various positron emission tomographies, and 
nonradioactive paramagnetic metal ions. See, for example, 
U.S. Pat. No. 4,741,900 for metal ions which can be con- 10 
jugated to antibodies for use in the present invention. 
Examples of suitable enzymes include horseradish peroxi-
dase, alkaline phosphatase, beta-galactosidase, or acetylcho-
linesterase; examples of suitable prosthetic group complexes 
include streptavidin/biotin and avidin/biotin; examples of 15 
suitable fluorescent materials include umbelliferone, fluo-
rescein, fluorescein isothiocyanate, rhodamine, dichlorotri-
azinylamine fluorescein, dansyl chloride or phycoerythrin; 
an example of a luminescent material includes luminol; 
examples of bioluminescent materials include luciferase, 20 
luciferin, and aequorin; and examples of suitable radioactive 
material include 1125 , 1131 , 1111 or TC99 . Ligands that bind to 
Pgrmc 1 and monoclonal and polyclonal antibodies that bind 
Pgrmcl, e.g., monoclonal and polyclonal antibodies raised 
against Pgrmcl peptides, e.g., a peptide consisting of or 25 
comprising SEQ ID NO: 1, including labeled or unlabelled 
binding ligands and antibodies may also be used to detect 
Pgrmcl in the methods of this invention. 
The kit of the present invention further comprises an 
instruction for use in aiding in diagnosing, monitoring 30 
progression of, or in the prognosis of, breast cancer. In an 
embodiment, the instruction provides that an elevated 
Pgrmcl level in a bodily fluid or in isolated exosomes as 
compared to a negative control, e.g., the level of Pgrmcl in 
the comparable bodily fluid or isolated exosomes from 35 
subject known not to have cancer, indicates an association 
with cancer. In yet another embodiment, the instruction in 
the kit instructs the isolation of the bodily fluid or exosome 
containing fraction of the bodily fluid from a subject at 
various intervals, e.g., weekly, monthly, biannually, annually 40 
etc, and the measurement and comparison of Pgrmcl levels 
in the bodily fluid or exosome containing fraction using the 
detection reagents in the kit. An increasing level of Pgrmc 1 
in the samples over time is associated with progression of a 
cancer, wherein a decreasing level of Pgrmcl in the samples 45 
over time is associated with regression of a cancer. 
The instructions in the kits of this invention may be 
present in a variety of forms, one or more of which may be 
present in the kit. One form in which these instructions may 
be present is as printed information on a suitable medium or 50 
substrate, e.g., a piece or pieces of paper on which the 
information is printed, in the packaging of the kit, in a 
package insert, etc. Yet another means would be a computer 
readable medium, e.g., diskette, CD, etc., on which the 
information has been recorded. Yet another form that may be 55 
present is a website address which may be used via the 
internet to access the information at a removed site. Any 
convenient form may be present in the kits. 
The kits may also comprise a computer or a component of 
a computer, such as a computer-readable storage medium or 60 
device. Examples of storage media include, without limita-
tion, optical disks such as CD, DVD and Blu-ray Discs 
(BD); magneto-optical disks; magnetic media such as mag-
netic tape and internal hard disks and removable disks; 
semi-conductor memory devices such as EPROM, 65 
EEPROM and flash memory; and RAM. The computer-
readable storage medium may comprise software encoding 
14 
references to the various therapies and treatment regimens 
disclosed herein. The software may be interpreted by a 
computer to provide the practitioner with treatments accord-
ing to various measured concentrations of Pgrmcl as pro-
vided herein. In various embodiments, the kit comprises a 
biomarker assay involving a lateral-flow-based point-of-care 
rapid test with detection of risk thresholds, or a biochip with 
quantitative assays for Pgrmcl. 
The following examples are offered by way of illustration, 
and are not limiting. 
EXAMPLE 1 
Pgrmcl Levels Correlate with Differentiation Status 
in Squamous Cell Lung Carcinoma 
In 15 matched samples of SCLC with adjacent nonma-
lignant tissue, Pgrmcl was overexpressed significantly in 
12/15 of the tumors relative to nonmalignant tissue from the 
same patient as determined by western blot in nonmalignant 
tissue (gray bars) and paired tumors (black bars) from the 
same patient. (FIG. lA). Samples 5, 13 and 14 were the 
exceptions (FIG. lA). A Pgrmcl-specific antibody recog-
nized elevated Pgrmcl levels in an SCLC tumor (FIG. 1B, 
upper panel, lane 2) compared to matched normal tissue 
(FIG. 1B, upper panel, lane 1 ). Pgrmcl recognized a band of 
25 kDa in nonmalignant tissue and a doublet of bands in the 
majority of tumors, and both bands were blocked by the 
immunogenic peptide, while neither band was recognized by 
preimmune serum (PIS) (FIG. 1B). Samples were analyzed 
in triplicate, and overall Pgrmcl levels relative to the 
matched nonmalignant tissue ranged from 0.7-fold to 
13-fold (FIG. lA, Samples 13 and 10, respectively). The 
increase in Pgrmcl was significant (p=0.01-0.05 for tumors 
1-4, 6-9 and 11-12, while p=0.002 for tumor #10 and 0.005 
for #15, t-test). Thus, Pgrmcl levels were elevated in 80% 
of SCLC relative to adjacent nonmalignant tissue from the 
same patient. There was little change between nonmalignant 
tissues in different patients (FIG. lA). Among the tumors in 
which Pgrmcl was induced by >5-fold relative to the 
adjacent nonmalignant tissue, 8/8 were poorly differentiated 
(FIG. lC, right column). In contrast, among the tumors with 
<4-fold Pgrmcl induction, 4/7 were moderately differenti-
ated. In the entire set of tumors, Pgrmcl levels correlated 
significantly with poor differentiation state (p=0.02, t-test). 
In contrast, Pgrmcl levels did not correlate with age at 
diagnosis or gender. As expected from the western blot 
analysis, immunohistochemistry revealed moderate staining 
in the normal tissue from Patient 4 (FIG. lD) and strong 
staining in the adjacent tumor (FIG. lF). A higher magni-
fication of the staining is shown as an inset for FIG. lF and 
demonstrated cytoplasmic staining. Cytokeratin staining of 
the same samples revealed abundant epithelial cells in the 
normal tissue (FIG. lE) and areas of concentrated epithelial 
cells in the tumor tissue (FIG. lG). Quantitation of three 
separate cytokeratin-positive areas for Pgrmcl staining 
demonstrated 2.3-fold higher Pgrmcl staining in the tumor 
epithelial cells compared to the same area of epithelial 
adjacent normal tissue (p=0.002, t-test). Notably, Pgrmcl 
was expressed in epithelial tumor cells as well as nonepi-
thelial adjacent cells (FIG. lF), suggesting a potential role 
for Pgrmcl in nonepithelial cells within tumors. 
EXAMPLE 2 
Pgrmcl Increases Viability in Squamous Lung 
Cancer Cell Lines 
Pgrmcl expression had not been characterized in 
squamous cell cancers previously, and Pgrmc 1 was readily 
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detectable in SW900, SKMES-1 and NCI-H226 cells (FIG. 
2A). Pgrmcl inhibition by RNA inhibition (RNAi) sup-
pressed proliferation in the non-small cell lung cancer 
(NSCLC) adenocarcinoma cell lineA549 but had little effect 
16 
on cell survival (Ahmed et al., J Pharmacal Exp Ther 2010; 5 
333:564-73). In contrast, RNAi of Pgrmcl in NCI-H226 
cells decreased the cell number (FIG. 2B), and the knock-
down of Pgrmcl expression was verified by western blot 
(FIG. 2C). Loss of viability after siRNA transfection was not 
through the apoptotic pathway, because the cleavage of 10 
caspase 3 and caspase 8 were unaffected (FIG. lA) and 
etoposide treatment served as a positive control for apopto-
and cancer free subjects by using well known methods in the 
art. We detected Pgrmcl in exosomes, and surprisingly also 
in unfractionated plasma, in both cancer patients and normal 
subjects. Met and PKM2 were used as markers for exosomes 
(Kimura et al. J Bioi Chern 2008; 283:4323-31; Kimura et 
al., J Neurochem 2010; 112:1156-67). Because exosomes 
require a lengthy purification process, most analysis were 
conducted with plasma. 
Pgrmc 1 was present in low but detectable levels in plasma 
of cancer free individuals (FIG. 4A, lanes 1-4). In contrast, 
Pgrmcl levels were significantly elevated in the plasma of 
8/11 lung cancer patients (FIGS. 4A, lanes 5-11 and 4B), 
including patients with adenocarcinoma, squamous cell car-
cinoma and large cell cancers (FIG. 4C). The Pgrmcl band 
was not detected with preimmune serum from the animal in 
which the anti-Pgrmcl antibody was raised (FIG. 4D, cen-
ter) or after addition of the immunogenic peptide (FIG. 4D, 
lower panel). 
sis (FIG. 18). 
Therapeutic options for SCLC are limited. However, a 
recently characterized Pgrmcl inhibitor, AG-205, efficiently 15 
inhibited the growth of NCI-H226 cells (FIG. 2F). The 
compound was most active in the absence of serum (FIG. 2F, 
solid line), where it had an IC50 of 9 µM. In the presence of 
serum, the compound had minimal activity (FIG. 2F, dashed 
line). Thus, Pgrmcl is expressed in cultured SCLC cell lines, 20 
where it promotes cell survival, and this activity is sup-
pressed by a Pgrmcl small molecule inhibitor. 
EXAMPLE 5 
Secretion Of Pgrmcl by Tumor Cell Lines and 
Effects of Pgrmcl on Tumor Cell Proliferation 
EXAMPLE 3 
Pgrmcl Levels Correlate with Survival in Lung 
Adenocarcinomas 
Pgrmcl promotes tumor formation and metastatic spread 
in adenocarcinoma cell lines. In a panel of 15 paired sets of 
lung adenocarcinomas with nonmalignant tissue from the 
same patient, Pgrmcl was significantly elevated in 6/15 
adenocarcinomas. Pgrmcl levels varied more in nonmalig-
nant tissue adjacent to the tumors than for squamous cell 
carcinomas (FIG. 3A). Similar to the SCLC analysis, the 
band recognized by the Pgrmcl antibody was blocked by the 
addition of immunogenic peptide (FIG. 3B, Patient 7 from 
FIG. 3A). 
To determine the clinical impact of Pgrmcl levels, tumors 
were grouped by low or high Pgrmcl tumor levels, and 
Pgrmcl levels correlated inversely with survival in the 
patients (FIG. 3C, p=0.035). There was a trend between 
survival and Pgrmcl levels in the nonmalignant tissues 
adjacent to the tumors that did not achieve significance. In 
contrast to SCLC, Pgrmcl levels did not correlate to a 
significant extent with differentiation status in this cohort of 
lung adenocarcinomas. As for squamous cell cancers (FIG. 
1), Pgrmcl was moderately expressed in tumor-adjacent 
normal lung tissue (FIG. 3D) and was detected in nonepi-
thelial cells adjacent to cytokeratin-positive lung tumor cells 
(FIGS. 3F and 3G). Cytokeratin staining revealed abundant 
epithelial cells in the nontumor tissue (FIG. 3E). Quantita-
tion of three separate cytokeratin-positive areas for Pgrmcl 
staining revealed 1.5-fold higher Pgrmcl staining in the 
adenocarcinoma epithelial cells compared to the same area 
of epithelial adjacent normal tissue (p=0.03, t-test). 
EXAMPLE 4 
Pgrmcl Detection in Plasma from Lung Cancer 
Patients 
We detected Pgrmcl/sigma2 receptor in endosomes 
within cancer cells and demonstrated the movement of 
25 To address the potential source of plasma Pgrmcl, we 
compared conditioned media from control or Pgrmc 1 knock-
down cells expressing a short hairpin RNA targeting 
Pgrmcl. Pgrmcl was abundant in media from the control 
cell line (FIG. SA, top, lane 1) but attenuated in the 
30 knockdown cell line (FIG. SA, top, lane 2). It is unlikely that 
Pgrmcl could be released from dead cells in the population 
because the cells were primarily arrested in Gl, with no 
evidence of sub-G 1 content (FIG. SB) or cell death under the 
conditions used for harvest (24 hr in no serum), and we were 
35 unable to detect the intracellular proteins GST-Pl and ku70 
in conditioned media (FIG. SA, media), even though they 
were abundant within the cells (FIG. SA, lysates). Pgrmcl 
was also readily detectable in the conditioned media of an 
SCLC cell line, H226 (FIG. SC). Secreted Neudesin/NENF 
40 (neuron-derived neurotrophic factor) and neuferricin stimu-
late growth in neurons (Kimura et al., J Neurosci Res 2005, 
79:287-94; Kimura et al., J Biol Chem 2008, 283:4323-31; 
Kimura et al., J Neurochem 2010,112:1156-67) and we 
found that purified, recombinant Pgrmcl had a similar 
45 activity towards A549 (FIG. SD) and H226 (FIG. SE) cells. 
Viability was measured by two different assays-mean cell 
count and MTT assays (FIGS. SD-SE, solid and dashed 
lines, respectively). 
The localization of Pgrmcl is highly variable in different 
50 cell types, with the protein localizing to the endoplasmic 
reticulum or secretory apparatus, plasma membrane and 
nucleus in various cell types (Nolte et al., Biochim Biophys 
Acta 2000, 1543:123-30; Min et al., FEBS J 2005, 272: 
5832-43; Marek et al., Comp Hepatol 2009, 8:1; Roy et al., 
55 Biochim Biophys Acta 2010,1804:1869-81; Ahmed J Biol 
Chem 2010; Peluso et al., Endocrinology 2006, 147:3133-
40; Krebs et al., Proc Natl Acad Sci USA 2000, 97:12816-
21; Shin et al., J Biol Chem 2003, 278:7607-16; Labom-
barda et al., J Neurochem 2003; 87:902-13). To determine 
60 the localization of Pgrmcl in squamous cell cancers, we 
transfected NCI-H226 cells with plasmids encoding green 
fluorescent protein (GFP) or GFP fused to Pgrmcl. Pgrmcl 
localized to punctate sites within the cytoplasm with mini-
mal nuclear staining (FIG. SF and FIG. 1). 
Pgrmcl/sigma2 receptor moving within cancer cells and 65 
could see it secreted (data not show). We purified plasma and 
the exosome fractions of plasma from lung cancer patients, 
Materials and Methods 
Tumor samples: All non-malignant and tumor solid tissue 
samples were obtained from the University of Kentucky 
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Biospecimen Core Program, and serum samples were 
obtained directly from the Markey Cancer Center. All pro-
tocols were approved by the Institutional Review Board. The 
clinical characteristics of the patients donating solid tumors 
are described in Table I. Tumor tissues and non-cancerous 5 
alveolar epithelial tissues from peripheral portions of the 
lung resection were collected based on gross characteristics 
(texture and color) with confirmed histological analysis. 
Non-cancerous tissues in the study were selected by the 
absence of neoplastic changes in the tissue, based on evalu- 10 
ation by the Director of the Tissue Procurement Facility, an 
Anatomic Pathology/Clinical Pathology board-certified 
pathologist. Tumors were classified as well, moderately or 
poorly differentiated by a certified pathologist (Table I). 
Immunohistochemistry was performed at the University 15 
of Kentucky Histology Laboratory with the Dako Envision 
kit (Dako, Carpinteria, Calif.), blocking in 3% bovine serum 
albumin and probing with an anti-Pgrmcl antibody (Pro-
teinTech Group, Chicago, Ill.). Sections from the same 
region of the normal or tumor tissue were imaged. Quanti- 20 
tation was with Adobe Photoshop and ImageJ software, 
analyzing median pixel density in three nonadjacent, cytok-
eratinpositive sections of the same samples. 
Western blotting: Tumor samples were disrupted in 
radioimmunoprecipitation (RIPA) buffer using a polytron 25 
P3000 homogenizer on ice. Samples were centrifuged at 
13,000xg for 10 minutes at 4° C, and the protein concen-
trations of the supernatants were measured by BCA assay. 
100 µg of each lysate was analyzed by western blot using the 
antibodies PGR-UKl (anti-Pgrmcl, raised to amino acids 30 
49-60, C-terminal to the putative membrane spanning 
sequence; Ahmed et al., J Pharmacol Exp Ther 2010; 333: 
564-73), anti-caspase 3 (Santa Cruz Biotechnologies, Santa 
Cruz, Calif.), anti-caspase 8 (Santa Cruz), anti-cytokeratin 
cocktail (AE1/AE3, Dako), anti-ku70 (Santa Cruz), anti- 35 
HAll (BAbCo, Richmond, Calif.) and anti-glutathione 
S-transferase (GST)-Pl (Genscript, Piscataway, N.J.). Pep-
tide blocking experiments were performed using an equimo-
lar amount of immunogenic peptide (amino acids 49-60 of 
Pgrmcl). Each sample of non-malignant tissue and adjacent 40 
tumor was analyzed in three separate western blots, using a 
reference protein sample (non-malignant tissue of adenocar-
cinoma patient #229) on each blot. All SDS-PAGE gels 
contained 10% acrylamide. The same tumors were analyzed 
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inhibition by small interferring RNA (siRNA) transfection 
and expression of a dominant-negative mutant has been 
described previously (Crudden et al. J Pharmacol Exp Tuer 
2006, 316:448-55), as has AG-205 treatment (Ahmed et al., 
2010). 
The methods for transfection with GFP-Pgrmcl expres-
sion plasmid pRC77 have been described (Ahmed et al. J 
Biol Chem 2010) and the GFP-Pgrmcl-D120G mutant was 
sub-cloned in the same manner as pRC77 from plasmid 
pRC45 (Crudden et al J Pharmacol Exp Ther 2006), result-
ing in plasmid pRC78. For adhesion assays, cells were 
transfected for 24 hours, transferred to chamber slides and 
incubated in serum-free medium for 5 days. The percent of 
green fluorescent cells attached to the substratum was scored 
in three separate fields for each transfected population. 
Conditioned media from control and Pgrmcl knockdown 
A549 NSCLC cells were generated by incubating cells in 
serum-free DMEM media for 24 hours. The media was then 
centrifuged and concentrated 10-fold (10 ml to 1 ml) using 
an Amicon Ultracel 10,000 molecular weight cut-off filter 
unit (Millipore, Billerica, Mass.). The concentrated medium 
was then incubated with 0.25 ml Separopore blue CL-6B 
slurry for 30 minutes and clarified by centrifugation at 
1 000xg for 3 minutes. H226 medium was concentrated 
similarly after incubating cells in serum-free medium for 24 
hours. For fluorescent activated cell sorting (FACS), cells 
were stained with propidium iodide and analyzed as 
described (Mallory et al., Mo! Pharmacol 2005, 68: 1747-
56). Purified Pgrmcl (Crudden et al., J Pharmacol Exp Ther 
2006; 316:448-55) was added to cells and cultured in serum 
free media. For viability assays, cells were plated in 24 well 
dishes, washed with PBS and harvested by trypsinization 
and counted using a hemocytometer. Where indicated, cells 
were plated in 96 well dishes, and viability was measured by 
3-( 4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay, as described (Hand and Craven. J Cell 
Biochem 2003, 90:534-47). 
Discussion 
In the present study, it is shown that secreted Pgrmcl is 
a biomarker for cancer, preferably SCLC and adenocarci-
noma of the lung. In addition to its elevation in lung tumors, 
Pgrmc 1 was also secreted by lung cancer cell lines and was 
elevated in the plasma oflung cancer patients. Finally, a role 
for Pgrmcl in SCLC cell survival is demonstrated, and a 
potential therapeutic approach for SCLC is presented. 
In SCLC, Pgrmcl was highest in the patients with poorly 
differentiated tumors, which correlates with survival in some 
lung tumors (Ichinose et al. J Thorne Cardiovasc Surg 1995, 
110:601-5. 47; Takise et al., Cancer 1988, 61:2083-8). 
by SDS-PAGE and stained with Coomassie Brilliant Blue. 45 
Three bands which were present in all of the samples were 
scanned and the sum of the bands was used to derive the 
loading control. Pgrmcl bands were quantitated using 
Adobe Photoshop and divided by the intensity of the refer-
ence band and loading controls. For the survival analysis, 
tumors were grouped into low Pgrmcl (sl relative to the 
normal control) or high Pgrmcl (>1) and analyzed by Cox 
regression analysis. 
50 Pgrmcl was readily detectable in SCLC cell lines, where its 
localization pattern resembled that of secretory vesicles, and 
Pgrmcl promoted cell proliferation in SCLC cells. There are 
limited therapeutic options for SCLC, and we found that a 
Pgrmcl inhibitor calledAG-205 (Ahmed et al., J Pharmacol For blood samples, plasma was centrifuged at 13,000xg 
for 10 minutes, and the supernatant was diluted 1:1 in 20 
mM Tris, pH 7.4 and incubated with 200 µI of Separopore 
blue CL-6B (Bio-world, Dublin, Ohio) slurry ( equilibrated 
in 20 mM Tris, pH 7.4) for 30 minutes. The slurry was then 
clarified by centrifugation at 1 000xg for 3 minutes and 5 µI 
of the supernatant was analyzed by western blot or SDS-
PAGE. 
Tissue culture: NIH-C226, SK-MES-1 and SW900 
squamous cell lung cancer cells and A549 lung adenocar-
cinoma cells were obtained from the American type culture 
collection (ATCC) and cultured according to their instruc-
tions. The identities of the cell lines were confirmed by 
Genetica DNA Laboratories (Cincinnati, Ohio). Pgrmcl 
55 Exp Ther 2010) inhibited SCLC growth. 
Pgrmcl is also over-expressed in AdcL. It was been 
shown that Pgrmc 1 promotes proliferation, migration, tumor 
growth and tumor metastasis in lung adenocarcinoma cells 
and furthermore, these cells were efficiently targeted with 
60 AG-205 (Ahmed et al., J Pharmacol Exp Ther 2010). The 
present study is an initial indication that Pgrmcl expression 
is elevated in a limited subset ( 40%) of patients, but that 
elevated Pgrmcl expressing tumors represent a subset with 
particularly poor outcome. While this observation will 
65 require validation in a larger cohort of patients, these 
patients may be an attractive population for testing Pgrmcl 
inhibitors in the future. 
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Pgrmcl is related to the secreted protein neudesin/NENF 
(neuron-derived neurotrophic factor)/Spuf (secreted protein 
of unknown function), and neudesin binds to an unknown 
receptor on neurons and elevates Akt signaling (Kimura et 
al., J Neurosci Res 2005, 79:287-94; Kimura et al., J Biol 5 
Chem 2008, 283:4323-31; Kimura et al., J Neurochem 2010; 
112:1156-67). Like its relatives, Pgrmcl was secreted by 
cancer cells and was detected in the plasma of healthy 
patients and at elevated levels in the plasma of lung cancer 
patients. Furthermore, Pgrmcl increased the proliferation of 10 
lung cancer cells, suggesting that it may have a direct 
pro-carcinogenic role in vivo. This is the first report of 
tumor-associated elevations in plasma Pgrmcl levels. How-
ever, the assay that we employed required a purification step 15 
that was not possible in archived samples, and survival data 
were not available for this study. Future research will 
delineate the clinical parameters associated with the patients 
containing high plasma Pgrmcl levels. The assay could also 
be improved with less intrusive enrichment steps. 
Together, the results suggest that Pgrmcl is a potential 
tumor and serum biomarker for lung cancer. Furthermore, in 
vitro results suggest that secreted Pgrmcl is active in 
promoting proliferation, similar to its homologues, although 
a potential receptor for Pgrmcl is not known. Plasma-
associated biomarkers would be particularly helpful for 
<160> NUMBER OF SEQ ID NOS, 1 
<210> SEQ ID NO 1 
<211> LENGTH, 12 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
SEQUENCE LISTING 
Gln Pro Ala Ala Ser Gly Asp Ser Asp Asp Asp Glu 
1 5 10 
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patients at risk for developing lung cancer, and a blood test 
could be significantly less expensive and less harmful than 
imaging. Pgrmcl is also a potential therapeutic target in lung 
cancer, and the detection of Pgrmcl in plasma may offer a 45 
means of identifying these patients with a facile screen. 
All publications and patent documents cited in this appli-
cation are incorporated by reference in their entirety for all 
purposes to the same extent as if each individual publication 
50 
or patent document were so individually denoted. By their 
citation of various references in this document Applicants do 
not admit that any particular reference is "prior art" to their 
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TABLE I-continued 
Patient sample characteristics 
Squamous lung 
cancers 
Adenocarcinomas 
Stage 
lA 
1B 
2A 
2B 
3A 
3B 
4 
Differentiation 
well 
moderately 
poorly 
I claim: 
Age 
53-82, average 65 
42-76, average 60 
Adena 
6 
0 
2 
2 
2 
2 
7 
5 
Squamous 
2 
5 
4 
0 
0 
0 
4 
11 
1. A method of facilitating the treatment of cancer in a test 
subject, the method comprising the steps of: (a) providing a 
body fluid sample from a test subject; (b) isolating exosomes 
from the body fluid sample; (c) measuring Pgrmcl level in 
the exosomes by using an immunoassay, ( d) comparing the 
level of Pgrmcl level in the exosomes with a the level of 
Pgrmcl in exosomes of a sample from a subject without 
cancer, and (e) treating the test subject having an elevated 
level of Pgrmcl with chemotherapy, immunotherapy, radia-
tion therapy, endoscopy, biopsy, or surgery. 
2. The method of claim 1, wherein the subject is a human. 
invention. 
TABLE I 
3. The method of claim 1 wherein the cancer is lung 
55 cancer, or head or neck cancer. 
Patient sample characteristics 
Squamous lung 
cancers 
Adenocarcinomas 
Squamous lung 
cancers 
Adenocarcinomas 
Sample numbers 
15 tumors, 15 non-malignant tissue 
15 tumors, 15 non-malignant tissue 
Gender 
10 male/5 female 
10 male/5 female 
60 
65 
4. The method of claim 1, wherein the immunoassay is 
ELISA, immunoblotting, or flow cytometry. 
5. The method of claim 1, wherein the body fluid is blood, 
plasma or serum. 
6. The method of claim 1 wherein the elevated Pgrmcl 
level is at least 2-fold greater than the level in the sample 
from the subject without cancer. 
7. The method of claim 1, wherein the immunoassay uses 
a polyclonal or monoclonal antibody. 
8. A method of detecting the presence of a cancer in a test 
subject and treating the test subject, wherein the test subject 
is suspected of having, or has a cancer, the method com-
US 10,288,626 B2 
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pnsmg: a) isolating exosomes from a bodily fluid sample 
from the test subject; contacting the exosomes with an 
antibody that specifically binds to Pgrmc 1; b) detecting the 
level of protein in the exosomes that specifically binds the 
antibody; and, c) comparing the level of protein in the 
exosomes to the level of protein that specifically binds the 
antibody in exosomes of a comparable normal bodily fluid 
sample; wherein an elevated level of protein in the exosomes 
of the test sample relative to the exosomes of the normal 
sample is an indication of the presence of the cancer in the 
individual, wherein the level of protein is detected in step b) 
by an immunoassay and d) treating the test subject having 
elevated Pgrmcl level as compared to the Pgrmcl level in 
exosomes of the normal bodily fluid sample with chemo-
therapy, immunotherapy, radiation therapy, endoscopy, 
biopsy, or surgery. 
9. The method of claim 8, wherein the antibody is a 
polyclonal or monoclonal antibody. 
10. The method claim 8, wherein the bodily fluid is blood, 
serum, or plasma. 
11. The method of claim 8, wherein the cancer is lung 
cancer, or head or neck cancer. 
12. The method of claim 8, wherein steps (a)-(c) are 
repeated and wherein a difference in the level of Pgrmcl in 
the samples of the test subject over time is indicative of 
progression or regression of the cancer. 
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13. A method for treating a subject suspected of having 
cancer, comprising detecting the level of Pgrmcl in exo-
somes isolated from the bodily fluid sample from a test 
subject suspected of having cancer and comparing the 
5 detected level with a reference level, wherein a Pgrmc 1 level 
in the exosomes of the sample of the test subject above the 
reference level is indicative of a higher risk of the test 
subject having cancer, wherein the detection of the level of 
the Pgrmcl is performed using an immunoassay, and then 
10 
administering chemotherapy, immunotherapy, radiation 
therapy, endoscopy, biopsy, or surgery to the test subject 
having Pgrmcl !eel above the reference level. 
14. The method according to claim 13, wherein the body 
15 
fluid is blood, plasma or serum. 
15. The method according to claim 13, wherein the 
immunoassay is an ELISA. 
16. The method of claim 14, wherein the cancer is lung 
cancer, or head or neck cancer. 
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17. The method according to claim 13, wherein the 
reference level is (a) the level of Pgrmcl in a comparable 
bodily fluid sample from a subject who does not have cancer 
or (b) an average of Pgrmc 1 in a comparable bodily fluid of 
subjects without cancer that is derived from population 
studies on subjects who did not develop cancer. 
* * * * * 
